仅因伊马替尼治疗慢性粒细胞白血病患者自发发生颌骨药物相关性骨坏死：1例罕见病例报告
Medication-Related Osteonecrosis of the Jaw Spontaneously Occurred in a Patient with Chronic Myelogenous Leukemia Only by Imatinib: A Report of a Rare Case.
作者信息
Okubo-Sato Makiko, Yamagata Kenji, Fukuzawa Satoshi, Terada Kazuhiro, Uchida Fumihiko, Ishibashi-Kanno Naomi, Bukawa Hiroki
机构信息
Department of Oral and Maxillofacial Surgery, Institute of Clinical Medicine, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8575, Japan.
出版信息
Case Rep Dent. 2021 Jan 27;2021:6621937. doi: 10.1155/2021/6621937. eCollection 2021.
The prevalence of medication-related osteonecrosis of the jaw (MRONJ) associated with molecular-targeted therapies such as bevacizumab and sunitinib has been constantly increasing in recent years. MRONJ frequently occurs after invasive dental procedures such as tooth extraction in patients currently or with a previous history of receiving antiresorptive agents including bisphosphonates and/or denosumab. Here, we report a rare case of spontaneously occurring MRONJ of the mandible in a 52-year-old Japanese woman with chronic myelogenous leukemia (CML) who was administered imatinib for 9 years. She had never been treated with antiresorptive agents, and her MRONJ developed spontaneously. Although there have been few reports of MRONJ related to imatinib, our case reported here indicates that imatinib may be capable of causing spontaneous MRONJ.
近年来，与贝伐单抗和舒尼替尼等分子靶向治疗相关的药物性颌骨坏死（MRONJ）的患病率一直在不断上升。MRONJ经常发生在目前正在接受或既往有接受包括双膦酸盐和/或地诺单抗在内的抗吸收剂治疗史的患者进行拔牙等侵入性牙科手术后。在此，我们报告一例罕见的52岁日本女性慢性粒细胞白血病（CML）患者，其接受伊马替尼治疗9年，下颌骨自发发生MRONJ。她从未接受过抗吸收剂治疗，其MRONJ为自发发生。虽然关于伊马替尼相关的MRONJ报道很少，但我们在此报告的病例表明伊马替尼可能会导致自发的MRONJ。
Zotero 插件